Price T Rowe Associates Inc. MD Buys Shares of 1,557,487 Metsera Inc. $MTSR

Key Points

• Price T Rowe Associates Inc. acquired 1,557,487 shares of Metsera Inc. valued at approximately $42.4 million, representing about 1.48% ownership in the company.
• Several institutional investors are showing strong interest in Metsera, with significant purchases from Alphabet Inc. ($135 million), T. Rowe Price ($78 million), and others during the first quarter.
• Metsera has a consensus rating of "Buy" from five analysts, with an average target price of $55, supported by recent ratings upgrades from Guggenheim and Wells Fargo.

Price T Rowe Associates Inc. MD bought a new stake in shares of Metsera Inc. (NASDAQ:MTSR - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,557,487 shares of the company's stock, valued at approximately $42,395,000. Price T Rowe Associates Inc. MD owned approximately 1.48% of Metsera at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of MTSR. Alphabet Inc. purchased a new position in Metsera during the 1st quarter valued at about $135,059,000. T. Rowe Price Investment Management Inc. purchased a new position in Metsera during the 1st quarter valued at about $78,748,000. Wellington Management Group LLP purchased a new position in Metsera during the 1st quarter valued at about $65,382,000. Vanguard Group Inc. purchased a new position in Metsera during the 1st quarter valued at about $39,932,000. Finally, Massachusetts Financial Services Co. MA purchased a new position in Metsera during the 1st quarter valued at about $13,111,000.

Metsera Stock Performance

MTSR opened at $35.02 on Thursday. The business has a 50 day moving average price of $33.73 and a 200 day moving average price of $28.44. Metsera Inc. has a twelve month low of $12.30 and a twelve month high of $47.40.

Metsera (NASDAQ:MTSR - Get Free Report) last posted its earnings results on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

Wall Street Analyst Weigh In

Several research firms have weighed in on MTSR. Wells Fargo & Company began coverage on Metsera in a research note on Friday, June 20th. They set an "overweight" rating and a $65.00 target price on the stock. Guggenheim boosted their price target on Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research note on Tuesday, June 10th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Metsera has a consensus rating of "Buy" and an average target price of $55.00.

Metsera Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.